[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559344":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":86,"collaborators":34,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":34,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":34,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":34,"overallStatus":54,"whyStopped":34,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Gilead Sciences","INDUSTRY",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A Single-ascending Dose (SAD) in Healthy Participants","EXPERIMENTAL","Participants will be randomized into 4 + (optional) 1 dose escalating cohorts and will receive GS-4571 or placebo to match (PTM) GS-4571 on Day 1, to determine the maximum tolerated dose:\n\n* Cohort 1: Dose 1 GS-4571, administered orally as a single dose, in a fasting state.\n* Cohort 2: Dose 2 GS-4571, administered orally as a single dose, in a fasting state.\n* Cohort 3: Dose 3 GS-4571, administered orally as a single dose, in a fasting state.\n* Cohort 4: Dose 4 GS-4571, administered orally as a single dose, in a fasting state.\n* Cohort 5 (optional): Dose 5 GS-4571, administered orally as a single dose, in a fasting state.",[13,14],"Drug: GS-4571","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part B Food\u002FPPI Effect in Healthy Participants","Participants will be randomized into 2 sequence groups in Cohort 6 and will receive the highest dose found to be safe and well tolerated in Part A of GS-4571 and omeprazole. The two sequential groups will receive the following treatments:\n\n* Treatment A: Up to the highest single dose of GS-4571 evaluated in Part A, fasting.\n* Treatment B: Up to the highest single dose of GS-4571 evaluated in Part A, nonfasting (high-fat\u002Fhigh-calorie meal).\n* Treatment C (optional): Omeprazole, once-daily (QD) for 5 days, fasting.\n* Treatment D (optional): Omeprazole followed by up to the highest single dose of GS-4571 evaluated in Part A, 2 hours later, fasting.",[13,19],"Drug: Omeprazole",{"label":21,"type":10,"description":22,"interventionNames":23},"Part C Multiple-ascending Dose (MAD) in Nondiabetic Obese Participants","Participants randomized in Cohorts 7-9 will be randomized to receive up to 4 escalating doses of GS-4571 or PTM QD for 12 weeks, as follows:\n\n* Cohort 7: Up to dose determined from Part A of GS-4571 or PTM in obese participants, QD, in a non-fasting state\n* Cohort 8: Up to 3-fold the Cohort 7 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state\n* Cohort 9: Up to 2-fold the Cohort 8 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state\n* Cohort 10 is optional and will receive GS-4571 or PTM QD for 12 weeks in case it is opened for enrollment as follows:\n\n  * Up to 2-fold the Cohort 9 dose of GS-4571 or PTM in obese participants, QD, in a non-fasting state.",[13,14],{"label":25,"type":10,"description":26,"interventionNames":27},"Part D Multiple Dose in Nonobese Participants With T2DM","Participants randomized in Cohort 11 will receive up to the highest dose of GS-4571 or PTM in T2DM, QD, in a non-fasting state for 12 weeks.",[13,14],[29,35,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","GS-4571","Administered orally",[9,16,21,25],null,{"type":30,"name":36,"description":32,"armGroupLabels":37,"otherNames":34},"Placebo",[9,21,25],{"type":30,"name":39,"description":32,"armGroupLabels":40,"otherNames":34},"Omeprazole",[16],[42],{"name":43,"affiliation":5,"role":44},"Gilead Study Director","STUDY_DIRECTOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":34,"email":50},"Gilead Clinical Study Information Center","CONTACT","1-833-445-3230 (GILEAD-0)","GileadClinicalTrials@gilead.com",[52,66,76],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":34},"Qps-Mra, Llc.","RECRUITING","Miami","Florida","33143","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-80.19366,25.77427,{"lat":64,"lon":63},{"facility":67,"status":54,"city":68,"state":69,"zip":70,"country":58,"countryCode":59,"cosmosGeoPoint":71,"geoPoint":75,"contacts":34},"ICON Early Phase Services, LLC","San Antonio","Texas","78232",{"type":61,"coordinates":72},[73,74],-98.49363,29.42412,{"lat":74,"lon":73},{"facility":77,"status":54,"city":78,"state":79,"zip":80,"country":58,"countryCode":59,"cosmosGeoPoint":81,"geoPoint":85,"contacts":34},"ICON","Salt Lake City","Utah","84124",{"type":61,"coordinates":82},[83,84],-111.89105,40.76078,{"lat":84,"lon":83},{"type":87,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100559344","phase-1-study-of-gs-4571-in-healthy-participants-nondiabetic-obese-participants-and-nonobese-participants-with-type-2-diabetes-mellitus-t2dm-100559344",false,"NCT06562907","Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571","Key Inclusion Criteria:\n\n* Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening.\n* Part A (SAD) and Part B (Food\u002FPPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with BMI of ≥ 19 and \\\u003C 30 kg\u002Fm\\^2, and no significant medical history.\n\nIndividuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose.\n\n* Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg\u002Fm\\^2 and \\\u003C 45 kg\u002Fm\\^2 with a total body weight \\> 50 kg, and nondiabetic (HbA1c \\\u003C 6.5%). Eligible individuals will also be individuals with stable body weight (\\\u003C 5% change) for 90 days prior to screening visit based on individual report.\n* Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \\\u003C 30 kg\u002Fm\\^2 and treated with diet and\u002For exercise, and\u002For metformin monotherapy.\n\nKey Exclusion Criteria:\n\n* Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes \\[with the exception of T2DM for individuals included in Part D only\\]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment.\n* Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening.\n* Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia).\n* Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator.\n* History of syncope, palpitations, or unexplained dizziness.\n* Active, or history of, significant cardiac disease or conduction abnormality\n* History of implanted defibrillator or pacemaker.\n* Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic steroids, immunosuppressant therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).\n* Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":100,"type":101},134,"ESTIMATED","INTERVENTIONAL",[104],"PHASE1","The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM).\n\nThe primary objectives of this study are:\n\n* To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571.\n* To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571.\n* To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.",[107],"Weight Management","2026-06-18",{"date":110,"type":111},"2026-06-22","ACTUAL",{"date":113,"type":111},"2024-08-28",{"date":115,"type":101},"2026-11",{"name":5,"class":6},3]